The Impact of Gender on Outcomes in Patients With Metastatic Urothelial Carcinoma

摘要: Abstract Background Although urothelial cancer is more common in men, women with have inferior survival outcomes. The potential existence of gender-related disparities patients metastatic has not been extensively explored. Patients and Methods Individual patient data were pooled from 8 phase II III trials evaluating first-line cisplatin-based combination chemotherapy carcinoma. Adverse events, treatment delivery, response proportions, outcomes compared between male female patients. Results Of the 543 included analysis, 100 (18%) women. There was no significant difference number cycles administered or proportions experiencing severe toxicities when comparing distributions ( P = .08); median 11.7 months (95% confidence interval [CI], 10.5-13.2) 16.2 for CI, 12.8-20.4). men controlling baseline performance status and/or presence visceral metastases. Conclusion Female tolerate similarly to achieve comparable clinical gender-associated cannot be completely ruled out, if such exist, they are unlikely related tolerability efficacy chemotherapy.